Investigation of Cardiac Amyloid Deposits as a Cause of Cardiac Dysfunction in Alzheimer's Disease (Untersuchung Von Kardialen Amyloidablagerungen Als Ursache Einer Funktionseinschränkung Des Herzens Bei Alzheimer Demenz)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Frequency of occurrence of cardiac amyloid deposits in patients with a diagnosis of Alzheimer's disease (overall)
研究概览
简要总结
This study seeks to explore the possible common pathogenesis of both cardiac amyloidosis and Alzheimer's disease, which can both be associated with amyloid deposits. Using Positron Emission Tomography (PET) scans with amyloid tracers - a conventional tool for non-invasively imaging amyloid deposits in Alzheimer's disease - the research will extend this imaging methodology to the heart.
The study will conduct additional PET/MRI scans of the heart in patients undergoing amyloid tracer PET scans for Alzheimer's evaluations. Each participant will also undergo an echocardiogram and a clinical examination of dementia.
This could potentially enhance diagnostic practices in both cardiac amyloidosis and Alzheimer's disease.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients undergoing cerebral amyloid PET examination for clinical indication to clarify Alzheimer's disease
- •No contraindications to undergo an MRI examination
- •No contraindications to undergo an Amyloid PET scan
排除标准
- •Patients with vascular dementia and confirmed other causes of dementia (e.g. stroke, vitamin deficiency, thyroid insufficiency, toxic causes such as alcohol)
- •Patients with pronounced cardiac preconditions
- •Pregnant and breastfeeding women
结局指标
主要结局
Frequency of occurrence of cardiac amyloid deposits in patients with a diagnosis of Alzheimer's disease (overall)
时间窗: through study completion, an average of 1 year
Frequency of occurrence of cardiac amyloid deposits in relation to different disease manifestations (subdivided, for example, by clinical assessment of disease stage)
时间窗: through study completion, an average of 1 year
次要结局
未报告次要终点